Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00085709 · FLOW

Participant flow

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML · Source last updated 2015-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C (cytosine arabinoside)and 3 days of daunomycin
    id
    FG000
    title
    Ara-C+Daunomycin+Mylotarg
  2. description
    Standard induction regimen of 7 days of Ara-C (cytosine arabinoside)and 3 days of daunomycin
    id
    FG001
    title
    ARA-C+Daunomycin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        0
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        2
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        2
      type
      Refusal unrelated to adverse events
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      type
      Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        12
      2. group Id
        FG001
        num Subjects
        22
      type
      Not protocol specified
    6. reasons
      1. group Id
        FG000
        num Subjects
        19
      2. group Id
        FG001
        num Subjects
        19
      type
      Not eligible
    7. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        1
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        317
      2. group Id
        FG001
        num Subjects
        320
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        298
      2. group Id
        FG001
        num Subjects
        301
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        296
      2. group Id
        FG001
        num Subjects
        300
      type
      Eligible and Did Not Withdraw Consent
    4. achievements
      1. group Id
        FG000
        num Subjects
        264
      2. group Id
        FG001
        num Subjects
        270
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        53
      2. group Id
        FG001
        num Subjects
        50
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C (cytosine arabinoside)and 3 days of daunomycin
    id
    FG000
    title
    Ara-C+Daunomycin+Mylotarg
  2. description
    Standard induction regimen of 7 days of Ara-C (cytosine arabinoside)and 3 days of daunomycin
    id
    FG001
    title
    ARA-C+Daunomycin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        0
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        2
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        2
      type
      Refusal unrelated to adverse events
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      type
      Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        12
      2. group Id
        FG001
        num Subjects
        22
      type
      Not protocol specified
    6. reasons
      1. group Id
        FG000
        num Subjects
        19
      2. group Id
        FG001
        num Subjects
        19
      type
      Not eligible
    7. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        1
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        317
      2. group Id
        FG001
        num Subjects
        320
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        298
      2. group Id
        FG001
        num Subjects
        301
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        296
      2. group Id
        FG001
        num Subjects
        300
      type
      Eligible and Did Not Withdraw Consent
    4. achievements
      1. group Id
        FG000
        num Subjects
        264
      2. group Id
        FG001
        num Subjects
        270
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        53
      2. group Id
        FG001
        num Subjects
        50
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice